Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. 2017

S V Glavey, and A Naba, and S Manier, and K Clauser, and S Tahri, and J Park, and M R Reagan, and M Moschetta, and Y Mishima, and M Gambella, and A Rocci, and A Sacco, and M E O'Dwyer, and J M Asara, and A Palumbo, and A M Roccaro, and R O Hynes, and I M Ghobrial
Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

The extracellular matrix (ECM) is a major component of the tumor microenvironment, contributing to the regulation of cell survival, proliferation, differentiation and metastasis. In multiple myeloma (MM), interactions between MM cells and the bone marrow (BM) microenvironment, including the BM ECM, are critical to the pathogenesis of the disease and the development of drug resistance. Nevertheless, composition of the ECM in MM and its role in supporting MM pathogenesis has not been reported. We have applied a novel proteomic-based strategy and defined the BM ECM composition in patients with monoclonal gammopathy of undetermined significance (MGUS), newly diagnosed and relapsed MM compared with healthy donor-derived BM ECM. In this study, we show that the tumor ECM is remodeled at the mRNA and protein levels in MGUS and MM to allow development of a permissive microenvironment. We further demonstrate that two ECM-affiliated proteins, ANXA2 and LGALS1, are more abundant in MM and high expression is associated with a decreased overall survival. This study points to the importance of ECM remodeling in MM and provides a novel proteomic pipeline for interrogating the role of the ECM in cancers with BM tropism.

UI MeSH Term Description Entries
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D005109 Extracellular Matrix A meshwork-like substance found within the extracellular space and in association with the basement membrane of the cell surface. It promotes cellular proliferation and provides a supporting structure to which cells or cell lysates in culture dishes adhere. Matrix, Extracellular,Extracellular Matrices,Matrices, Extracellular
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D017306 Annexin A2 A member of the annexin family that is a substrate for a tyrosine kinase, ONCOGENE PROTEIN PP60(V-SRC). Annexin A2 occurs as a 36-KDa monomer and in a 90-KDa complex containing two subunits of annexin A2 and two subunits of S100 FAMILY PROTEIN P11. The monomeric form of annexin A2 was formerly referred to as calpactin I heavy chain. Annexin II,Calpactin I,Lipocortin II,Annexin A2, P90 Complex,Annexin II, P36,Annexin II, P90 Complex,Capactin I Heavy Chain,P36 Annexin II
D059016 Tumor Microenvironment The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth. Cancer Microenvironment,Cancer Microenvironments,Microenvironment, Cancer,Microenvironment, Tumor,Microenvironments, Cancer,Microenvironments, Tumor,Tumor Microenvironments
D020543 Proteome The protein complement of an organism coded for by its genome. Proteomes
D020869 Gene Expression Profiling The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell. Gene Expression Analysis,Gene Expression Pattern Analysis,Transcript Expression Analysis,Transcriptome Profiling,Transcriptomics,mRNA Differential Display,Gene Expression Monitoring,Transcriptome Analysis,Analyses, Gene Expression,Analyses, Transcript Expression,Analyses, Transcriptome,Analysis, Gene Expression,Analysis, Transcript Expression,Analysis, Transcriptome,Differential Display, mRNA,Differential Displays, mRNA,Expression Analyses, Gene,Expression Analysis, Gene,Gene Expression Analyses,Gene Expression Monitorings,Gene Expression Profilings,Monitoring, Gene Expression,Monitorings, Gene Expression,Profiling, Gene Expression,Profiling, Transcriptome,Profilings, Gene Expression,Profilings, Transcriptome,Transcript Expression Analyses,Transcriptome Analyses,Transcriptome Profilings,mRNA Differential Displays

Related Publications

S V Glavey, and A Naba, and S Manier, and K Clauser, and S Tahri, and J Park, and M R Reagan, and M Moschetta, and Y Mishima, and M Gambella, and A Rocci, and A Sacco, and M E O'Dwyer, and J M Asara, and A Palumbo, and A M Roccaro, and R O Hynes, and I M Ghobrial
September 2007, Journal of clinical pathology,
S V Glavey, and A Naba, and S Manier, and K Clauser, and S Tahri, and J Park, and M R Reagan, and M Moschetta, and Y Mishima, and M Gambella, and A Rocci, and A Sacco, and M E O'Dwyer, and J M Asara, and A Palumbo, and A M Roccaro, and R O Hynes, and I M Ghobrial
June 2005, Leukemia & lymphoma,
S V Glavey, and A Naba, and S Manier, and K Clauser, and S Tahri, and J Park, and M R Reagan, and M Moschetta, and Y Mishima, and M Gambella, and A Rocci, and A Sacco, and M E O'Dwyer, and J M Asara, and A Palumbo, and A M Roccaro, and R O Hynes, and I M Ghobrial
February 2014, Journal of proteome research,
S V Glavey, and A Naba, and S Manier, and K Clauser, and S Tahri, and J Park, and M R Reagan, and M Moschetta, and Y Mishima, and M Gambella, and A Rocci, and A Sacco, and M E O'Dwyer, and J M Asara, and A Palumbo, and A M Roccaro, and R O Hynes, and I M Ghobrial
September 1994, Leukemia research,
S V Glavey, and A Naba, and S Manier, and K Clauser, and S Tahri, and J Park, and M R Reagan, and M Moschetta, and Y Mishima, and M Gambella, and A Rocci, and A Sacco, and M E O'Dwyer, and J M Asara, and A Palumbo, and A M Roccaro, and R O Hynes, and I M Ghobrial
July 2018, Endocrinology,
S V Glavey, and A Naba, and S Manier, and K Clauser, and S Tahri, and J Park, and M R Reagan, and M Moschetta, and Y Mishima, and M Gambella, and A Rocci, and A Sacco, and M E O'Dwyer, and J M Asara, and A Palumbo, and A M Roccaro, and R O Hynes, and I M Ghobrial
March 2022, Neoplasma,
S V Glavey, and A Naba, and S Manier, and K Clauser, and S Tahri, and J Park, and M R Reagan, and M Moschetta, and Y Mishima, and M Gambella, and A Rocci, and A Sacco, and M E O'Dwyer, and J M Asara, and A Palumbo, and A M Roccaro, and R O Hynes, and I M Ghobrial
April 2003, British journal of haematology,
S V Glavey, and A Naba, and S Manier, and K Clauser, and S Tahri, and J Park, and M R Reagan, and M Moschetta, and Y Mishima, and M Gambella, and A Rocci, and A Sacco, and M E O'Dwyer, and J M Asara, and A Palumbo, and A M Roccaro, and R O Hynes, and I M Ghobrial
January 2022, Frontiers in immunology,
S V Glavey, and A Naba, and S Manier, and K Clauser, and S Tahri, and J Park, and M R Reagan, and M Moschetta, and Y Mishima, and M Gambella, and A Rocci, and A Sacco, and M E O'Dwyer, and J M Asara, and A Palumbo, and A M Roccaro, and R O Hynes, and I M Ghobrial
October 2022, Blood,
S V Glavey, and A Naba, and S Manier, and K Clauser, and S Tahri, and J Park, and M R Reagan, and M Moschetta, and Y Mishima, and M Gambella, and A Rocci, and A Sacco, and M E O'Dwyer, and J M Asara, and A Palumbo, and A M Roccaro, and R O Hynes, and I M Ghobrial
April 2009, Current pharmaceutical biotechnology,
Copied contents to your clipboard!